All In Biotech

NDA 215650 · Organon LLC

Xaciato

Clindamycin Phosphate · Vaginal

Priority review

Last checked: Nov 20, 2026Latest source record: Mar 6, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 7, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

3,566

2,260 serious, 264 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 19, 2026.

XACIATO is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. ( 1.1 ) 1.1 Bacterial Vaginosis XACIATO ® is indicated for the treatment of bacterial vaginosis in females 12 years and older [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14 )] .

Mechanism: Clindamycin is an antibacterial drug [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 7, 2021 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
1 products under this application
  • XACIATO · CLINDAMYCIN PHOSPHATE EQ 2% BASE · GEL, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective375
  • rash257
  • drug hypersensitivity230
  • off label use227
  • diarrhoea190
  • nausea186
  • fatigue169
  • pruritus168
  • pain161
  • condition aggravated135
  • dyspnoea114
  • headache113

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200418
200548
200656
200714
200820
200943
201082
201165
201295
2013101
2014102
2015124
2016242
2017182
2018237
2019276
2020210
2021194
2022288
2023305
2024286
2025309
2026268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xaciato (Clindamycin Phosphate)

2024 spending

$14K

Beneficiaries

55

65 claims

Per beneficiary

$255

$19.34 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$14,002

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,207 on PubMed

Sponsor: Organon LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.